Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sofgen Pharma S.A (PROCF) Fair Value & Analysis

Healthcare · US · Market cap $58.4M

Price$0.0251
Fair Value$0.0265
Upside+5.5%
Quality87/100
Evidence: Low Range $0.0230 – $0.0297

Fair value as of: Jun 26, 2026

Analysis

Sofgen Pharma S.A (PROCF) currently trades at $0.0251, while our model-based Fair Value estimate is $0.0265 — implying the stock looks roughly 5.5% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical products, such as Advil, Apronax Liquidgels, multivitamins, Vitamin D, and Dolex ActivGel. It also formulates, manufactures, and markets branded prescription drugs in therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory; and manufactures and markets personal high-complexity drugs for hospital use comprising antibiotics, blood clot, immunosuppressant, oncology, and analgesics products…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Sofgen Pharma S.A (PROCF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0265 versus a price of $0.0251 — about +6% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PROCF?
Our 21-model fair value for Sofgen Pharma S.A is $0.0265 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0251.
What is the quality score of PROCF?
Sofgen Pharma S.A has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.